Oncopeptides to host Capital Markets Update November 13
Oncopeptides will host a Capital Markets Update on November 13, 2025, from 09:00 to 12:00 CET, broadcast live from Inderes studio in Stockholm.
The event will provide shareholders and investors with a deeper understanding of the company’s strategic direction, growth plans, and expanding role in the evolving treatment landscape for multiple myeloma.
The half-day program will feature presentations and discussions with leading international experts from Europe, Japan, and the U.S., offering clinical, scientific, and market perspectives. Confirmed speakers include:
- Prof. Dr. Sebastian Theurich, LMU University Hospital Munich
- Dr. María-Victoria Mateos, University of Salamanca
- Dr. Claudio Cerchione, IRST IRCCS, Italy
- Prof. Dr. med. Klaus Fenchel, Germany
- Prof. Shinsuke Iida, Nagoya City University, Japan
- Prof. Paul G. Richardson, Dana-Farber Cancer Institute / Harvard Medical School, U.S.
The event will also feature Dr. Björn Odlander, Founder & Managing Partner of HealthCap, and Sofia Heigis, CEO of Oncopeptides, who will share insights on the company’s business outlook and investment case.
How to attend:
The event will be held in English and streamed live. A recording will be available on-demand below.
Full agenda
The event will be held in English. All times in CET. Agenda subject to change.
09.00 – 09.03 | Welcome
Speaker: David Augustsson, Director of IR, Oncopeptides.
09.03-09.20 | Bringing Hope through Science
Speaker: Sofia Heigis, CEO, Oncopeptides.
09.20-09.30 | Owner’s perspective
Speaker: Dr. Björn Odlander, founder and managing partner, HealthCap.
09.30-9.55 | Keynote 1: Multiple myeloma and the unmet medical need
Speaker: Prof. Dr. Sebastian Theurich.
Description: An introduction to multiple myeloma and the treatment landscape, emphasizing the need for new treatments in the 4L+ stage.
9.55-10.00 | From Need to Treatment – A Clinician’s Reflection
Speaker: Dr. María‑Victoria Mateos.
Description: Dr. Mateos shares her perspective on the evolving treatment landscape and the clinical relevance of Pepaxti in addressing unmet needs in relapsed and refractory multiple myeloma.
10.00-10.25 | Conversation: Relapsed, refractory multiple myeloma – clinical experience with Pepaxti
Speakers: Dr. Claudio Cerchione, Prof. Dr. med. Klaus Fenchel.
Description: A conversation on the European multiple myeloma landscape and the treatment challenges facing today´s healthcare practitioners.
10.25-10.35 | BREAK
10.35-10.45 | Keynote 2: The Japanese Multiple Myeloma landscape
Speaker: Prof. Shinsuke Iida.
10.45-10.55 | Keynote 3: The potential of the PDC platform in the U.S.
Speaker: Prof. Paul Richardson.
10.55-11.30 | Oncopeptides as an investment case – where do we go from here?
Speaker: Sofia Heigis, CEO, Oncopeptides.
11.30-11.45 | Questions and Answers from investors
All in-person participants.
11.45-11.50 | Closing remarks
Speaker: Sofia Heigis, CEO, Oncopeptides.